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Abstract
Gene therapy is a therapeutic strategy that aims to employ nucleic acids as drugs for 
the transient or permanent treatment of inherited or acquired pathologies. Based on the 
type of vector employed for the gene transfer, gene therapy can be classified as viral 
gene therapy and nonviral gene therapy. Nonviral gene therapy is less efficient but safer 
than viral gene therapy. Hydrodynamic naked DNA transfer has shown great transla-
tional potential, achieving therapeutic levels of a human protein in the murine model. 
The translational process of the procedure has already been performed. Different radio-
logic and surgical approaches permitted pressurizing the liver in vivo by excluding its 
vascularization partially or totally. These approaches mediated a tissue rate of human 
alpha-1-antitrypsin protein translation (100–1000 copies per cell) close to those obtained 
with the mouse gold standard model in a safe mode that could be translated to human 
settings.
Keywords: gene therapy, liver, hydrodynamic, radiologic, catheterization, 
transplantation, surgery
1. Introduction
Gene therapy is a therapeutic strategy that uses nucleic acids, in any of their forms, as a drug 
for the transient or permanent treatment of inherited or acquired pathologies [1]. From a reg-
ulatory point of view, these drugs are considered in the European Regulation 1394/2007 and 
the Directive 2001/83/CE of the European Parliament. These, basically, establish the following:
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
“A gene therapy drug is a biologic drug with the following features:
a. it includes an active principle that contains a recombinant nucleic acid, or it is constituted 
by this, and it is employed or administered in human beings, aiming to regulate, repair, 
substitute, add or remove a gene sequence;
b. its therapeutic, prophylactic or diagnostic effect depends directly on the nucleic acid se-
quence or its expression product.”
Gene therapy consists of the transfer of a gene with clinical interest to the target tissue or organ of a 
patient. This transfer can be mediated by a vector or vehicle or employing naked DNA. Gene ther-
apy aims that the gene reaches the target cells with sufficient molecular bioavailability for the host 
cell’s decoding machinery to decode the gene sequence and produce the protein encoded by it [2].
The correct production of the protein encoded by the transferred gene would permit:
a. adding a new function to the target cell
b. recovering a lost or diminished function
c. inhibiting or modulating an exacerbated function
d. editing the genome to correct the production of a defective protein
1.1. Gene therapy strategies
There are different alternatives to perform the gene transfer. Depending on the resource 
employed for the delivery procedure, gene therapy can be classified as viral and nonviral.
1.1.1. Viral gene therapy
Viral gene therapy employs a viral vector to carry the DNA of interest to the nucleus of the target cell 
[3]. This viral vector consists of the sequence of a virus, integrative or not, without the pathogenic 
sequences (related with its replicative ability), which are substituted by the therapeutic gene of 
interest. This strategy takes advantage of the viral ability to access the cells and employ their decod-
ing machinery to translate its own genome. Viral gene therapy offers the following advantages:
a. It mediates a more efficient transfer of the gene;
b. Its administration could be systemic since the virus structure protects the gene from the 
circulating nucleases;
c. It permits developing permanent (employing viral vectors with the ability to integrate 
within the host cell genome) or transient (employing non-integrative viruses such as ad-
enoviruses) therapies;
d. It is possible to select the target cell since some viruses present tropism.
However, they also present disadvantages to be considered:
a. Some viruses can induce intense immune responses, limiting the repeated doses (especially 
relevant in adenoviral vectors);
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b. The exact place of the host genome where viruses integrate their genome is still unknown, 
hence being possible to alter the normal cell functions (insertional mutagenesis, tumor 
transformation);
c. Although not probable, it is possible that the viral particle without pathogenic features 
could recover them by genetic recombination, resulting in a potential risk for its clinical use.
1.1.2. Nonviral gene therapy
Nonviral gene therapy consists of the delivery of DNA mediated by the use of a nonviral vec-
tor [4–6] or the delivery of naked DNA [7], by physical procedures. With the aim of protect-
ing the delivered DNA from its degradation exerted by circulating nucleases, different types 
of nonviral vectors have been designed. These vectors can facilitate the DNA (negative net 
charge) access into the cell through its plasmatic membrane, also negatively charged. Among 
the different models of nonviral vectors, we can find:
a. Liposomes—formed by the inclusion of DNA molecules within the lipid’s concentric lay-
ers. They have the ability to protect the gene and facilitate its cell internalization by endocy-
tosis and/or fusion with the cell membrane in order to release the DNA inside the cell [6, 8].
b. Polyplexes [6, 9]—they employ biodegradable polymers that protect the DNA from the 
degradation mediated by DNAses. The use of cationic lipids or polymers permits the for-
mation of complexes with the DNA (lipoplexes and polyplexes, respectively) that facili-
tates its cell internalization.
Dewadvantages of nonviral vectors, they have limited utility because of their difficult formulation 
for clinical application. Their efficiency in ‘in vitro’ experiments is much higher than the efficiency 
observed in ‘in vivo.’ Furthermore, they have sometimes induced the immune response in patients.
Since viral gene therapy has offered good transfer efficiency but with the potential risk of 
immune reaction, or even that the recovery of virus infectivity and gene therapy mediated by 
nonviral vectors does not offer real advantages, physical procedures for efficient and safe naked 
DNA transfer have been developed. The most important alternatives of these strategies are:
a. Electroporation consists of augmenting the cell membranes’ permeability by employing elec-
tric pulses [6, 10, 11]. It increases the transfer efficiency but is more targeted to muscular tissue;
b. Sonoporation consists of the application of ultrasound on a biological tissue, mediating 
the formation of bubbles that create a stir able to destabilize transiently the cell membrane 
and facilitating the access of gene [6, 12];
c. Magnetofection based on the application of a magnetic field after the transfer of a gene 
linked to metallic particles in order to lead the product inside the tissue. This strategy has 
not demonstrated important improvement [13, 14];
d. Jet injection consists of the high-speed injection of particles. It is employed specifically in 
muscle tissue [15–17];
e. Hydrodynamic gene transfer is mediated by changes in cell permeability induced by the 
intravascular injection of DNA saline solution (hydrofection). This has proved to be one 
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Figure 1. Gene therapy clinical trials approved in the world. In this figure, the number of gene therapy clinical trials 
approved in the world each year since 1989 until August 2016 is shown. Source: www.wiley.co.uk/genmed/clinical [21].
of the most promising methods for naked DNA transfer and presents a great potential of 
clinical application in several different organs [18, 19].
1.2. Gene therapy in clinics
Since the approval of the first gene therapy clinical trial performed in patients in 1989, the 
number of these clinical trials, with little fluctuations, has increased constantly [20] achieving 
approximately 2600 in total (updated in November 2017) with a maximum rate of 169 clinical 
trials approved in 2015 (Figure 1).
The increasing use of gene therapy was possible, thanks to the development of gene con-
structs by employing different genes depending on the therapeutic application. Among the 
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most employed, those modulating the immune response (by activation or repression) stand 
out from the others. In clinical trials, the most employed strategy for gene transfer has been 
viral gene transfer (around 70%). Adenoviruses (A) due to their capacity to carry large genes 
and express them transiently and retroviruses (R) because of their ability to integrate the gene 
within the host genome permitting its long-term stable expression (suitable for inherited defi-
ciencies) are the most employed. The most employed strategies of nonviral gene therapy in 
clinical trials have been the lipofection and naked DNA (N), since they are the safest (Figure 2).
However, when clinical trials employing naked DNA for monogenic inherited diseases are 
searched, only six trials are found and when considering genes encoding cytokines, only one 
is found. Despite the different strategies to vectorize the gene and the types of treatment 
employed, only 0.1% of all clinical trials employing gene therapy reached phase IV (Table 1).
Among all the gene therapy procedures, the one that achieved the most positive benefit-
risk balance has been the naked DNA hydrodynamic transfer. Given the potential interest 
Figure 2. Vectors used in gene therapy clinical trials. Source: www.wiley.co.uk/genmed/clinical [21].
Phase Number of clinical trials Ratio (%)
I 1409 57.2
I/II 500 20.3
II 429 17.4
II/III 24 1
III 91 3.8
IV 3 0.1
Single subject 5 0.2
Source: www.wiley.co.uk/genmed/clinical [21].
Table 1. Phases of gene therapy clinical trials.
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Figure 3. Schematic representation of sinusoid organization after retrograde hydrodynamic injection of gene solution. 
When a plasmid is injected, vessel pressure increases inducing the separation of endothelium cells. This permits the 
access of gene constructs to the Disse space and to the hepatocytes through the massive formation of endocytic vesicles.
of hydrodynamic gene therapy and the wide range of application in clinics (especially in 
the liver), the translational process of the technique has been performed from the successful 
murine model to human liver segments. The swine model permitted adapting the procedure 
for ‘in vivo’ liver transfer. Different radiologic and surgical approaches performed to improve 
the liver hydrodynamic gene transfer ‘in vivo’ will be discussed in this chapter.
2. Hydrodynamic naked DNA transfer
2.1. Hydrodynamic methodology
The possibility of expressing heterologous genes with high efficacy after the delivery of 
naked DNA was firstly described during the mid-1990s [22, 23]. In 1999, Zhang et al. [24] 
and Liu et al. [25] introduced the hydrodynamic gene transfer procedure. This procedure 
consisted of the rapid injection of a large volume (2 ml in 5–7 s) of saline solution bearing 
the gene of interest through the tail vein in the mouse (20 g average weight). The possibil-
ity of transferring naked DNA efficiently aroused a great interest among researchers and 
clinicians since the hydrodynamic procedure permitted expressing high levels of a heterolo-
gous protein, employing a safer strategy than viral gene therapy. Different research groups 
focused their efforts on improving the technique in order to be safer, more efficient and 
reproducible [26].
2.2. Hydrofection mechanism
In Figure 3, the sinusoid circulation within the liver before and after the retrograde injec-
tion of a saline solution containing a plasmid is shown. The gene solution injected through 
the tail vein reaches the liver in a retrograde sense and increases the pressure inside the 
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vessel. This distends the wall mediating the transient separation of endothelium cells. 
When this occurs, the DNA leaves the blood vessels through the sinusoid pores and inter-
cellular spaces and reaches the Disse space. From this space, the DNA can access the hepa-
tocyte, the massive formation of endocytic vesicles playing a relevant role in this process. 
This DNA must reach the nucleus of the hepatocyte in order that the gene information 
delivered can be decoded. When this process takes place efficiently, the DNA is transcribed 
to RNA and this is translated to the protein, which is released into the bloodstream (in case 
of plasma proteins).
Employing this procedure, therapeutic plasma levels of alpha-1-protein were achieved for 
periods of more than 6 months in mice [27]. Nowadays, many gene therapy experiments for 
different pathology treatments are being studied in mice [28–30]. The possibility of achieving 
therapeutic levels of heterologous proteins after hydrodynamic human gene transfer in the 
murine model boosted the efforts of research teams to develop and adapt the procedures in 
larger animals aiming to translate it into the clinics, since the hemodynamic changes induced 
by the hydrodynamic injection are not compatible with its use in humans.
The perfusion conditions that permitted achieving the most efficient results in the mouse 
implied doubling the animal’s volemia in a very short period of time. The procedure had 
to be necessarily adapted since larger animals would have not tolerated these conditions. 
The modifications of the procedure were directed to diminish the systemic hydrodynamic 
pressure. This was performed by transferring the gene of interest to the one and only target 
organ by image-guided catheterization procedures. Studies were performed in rats [31, 32] 
and rabbit [33] models but the results obtained were much less efficient than that observed 
in the mouse. The most recent efforts focused on developing models of liver hydrodynamic 
perfusion in pigs given their anatomical proximity with humans [34].
In the swine model, different strategies for minimally invasive gene transfer were designed 
through liver catheterization [35, 36]. Although these procedures proved to be safe, the effi-
ciency achieved was not remarkable. Some authors highlighted the possibility that higher 
intravascular pressure within the liver could be required. For this reason, different strate-
gies to block the venous backflow and employ more demanding perfusion conditions were 
studied. Levels of heterologous protein expression were not close to therapeutics in any case. 
After several works carried out by research groups around the world, no significant result was 
achieved [37–41]. However, given the huge interest of this procedure and its potential to be 
translated to human clinical practice, different groups evaluated minutely the molecular pro-
cess of the transferred gene decoding in order to confirm or refuse this possibility. Evaluating 
at molecular level the detailed delivery, transcription and translation of a transferred gene 
permitted in identifying the step of the decoding process that limited the final efficacy in 
liver tissue and comparing this process in different animal models: mouse, pig and human. 
The best conditions of efficacy and safety for liver hydrodynamic gene therapy have been 
established in pig liver ‘in vivo’ (by catheterization and surgery) and the human liver ‘ex vivo’ 
(by catheterization in watertight segments). The methodology permitted comparing quantita-
tively the efficiency of different procedures of liver gene transfer. These procedures included 
partial and complete vascular exclusion aiming to pressurize the organ without affecting the 
systemic hemodynamics.
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2.3. Therapeutic targets
Since gene transfer can deliver a gene functionally complete to the cell, it presents a great 
interest for the treatment of inherited metabolic diseases [42–45], such as alpha-1-antitrypsin 
deficiency [46], in which the entire functional gene could be implemented.
Gene therapy can also play an important role in the treatment of different acquired patholo-
gies. Its application for modulating the immune response in different proinflammatory 
conditions, such as liver transplantation, has been studied by implementing genes of anti-
inflammatory cytokines such as interleukin-10 (IL10).
3. Clinical translation of hydrodynamic gene therapy
Several animal models have been employed for hydrodynamic gene transfer. The murine 
model has resulted in the gold standard of the procedure since therapeutic levels of the pro-
tein encoded by the transferred gene have been achieved. The translational process has been 
carried out in rat, rabbit, guinea pig, dog, pig and human liver segments.
The murine model consisted of the rapid injection of gene saline solution in a volume equiva-
lent to the animal volemia. This large volume facilitates the backflow of the gene solution and 
provokes its retrograde access to the liver. The high heart rate of the mouse permits the injection 
of such volumes with animal survival. Similar conditions to those employed for mice were car-
ried out in rats, although different adaptations for diminishing the solution volume have been 
proposed in order to follow up the translation process. Other researchers [47] studied different 
strategies to improve hydrodynamic gene delivery efficiency by targeting the right lateral liver 
lobe of the rat through the portal vein branch. The need for outflow blockade in the target area 
was reported since the portal vein pressure was too low to avoid backflow. In another attempt 
to improve the efficiency of the procedure, the left liver lobe was targeted in the rat and outflow 
occlusion was performed to compare its effect to free-flow control rats [32]. It was reported that 
outflow blockade is demanding to obtain efficient outcomes in transgene expression. Larger ani-
mals do not have the ability to increase the heart rate as mice and doubling their volemia would 
be incompatible with survival. Thus, the hydrodynamic injection had to be adapted to reduce 
the final volume and minimize the systemic hemodynamic impact. These adaptations focused 
on targeting an organ. Regarding this fact, Eastman et al. injected a gene to a single liver lobe 
employing a balloon catheter and to the entire organ of the rabbit with hepatic venous occlusion 
and achieved protein plasma expression in 2 days. The safety of the liver hydrodynamic gene 
transfer was also assessed in dogs to prove its feasible application in large animals [48]. They 
performed four successive injections in four different main liver lobes. Authors observed no sig-
nificant harmful effects and rapid recovery of animals. However, the results obtained were poor.
The following step for the clinical translation of the procedure was to test its potential use 
in anatomically more similar animals to human beings such as pigs and primates. The tech-
niques for gene delivery that were employed should be applicable in human settings.
Yoshino et al. [35] and Aliño et al. [36] described the first attempts performed in a pig. The 
total volume employed was reduced by targeting an area of liver and compared different 
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catheter-mediated delivery strategies. These strategies included portal vein occlusion, left 
hepatic artery occlusion, portal vein and left hepatic artery occlusion and both vessels’ occlu-
sion with blood flow washout. Yoshino et al. injected the gene solution through the cava vein. 
The occlusion of portal vein and hepatic artery with the washout mediated the most efficient 
outcomes achieving disperse protein plasma levels for several weeks. For the first time, the pro-
cedure showed interesting results in pigs, for those proteins with low expression. In another 
work, hydrodynamic retrovenous gene transfer was performed in large and small areas of pigs’ 
liver. Alino et al. [36] reported the presence of gene and protein expression in tissues, mainly 
within the perivenous area. Targeting smaller areas but employing same volumes of gene solu-
tion, higher plasma protein levels were achieved, much lower than those considered therapeutic. 
Fabre et al. [37] targeted the entire liver and isolated the hepatic segment of the inferior vena cava 
by clamping it suprahepatically and infrahepatically. Gene solution was transferred by a hydro-
dynamic procedure through two parallel syringes and, although the efficiency of gene delivery 
was much lower than the one observed in the mouse and rat, they confirmed the clinical feasibil-
ity of the technique as determined by systemic blood pressures, ECG, heart rate and so on.
Pressure reached within the liver during the hydrodynamic injection played an important 
role. For this reason, Fabre et al. [40] focused their work on pressurizing individual lobes 
of the liver by isolating them. Aiming to achieve localized high pressure without affecting 
the systemic circulation, they proposed individualizing the lobe by employing catheters with 
balloon and ligation. Although most of the authors suggested blood pressure to be the most 
important feature of hydrodynamic injection for efficient gene transfer, others have pointed 
other characteristics such as impulse [49] and flow rate [50, 51] to be relevant. However, 
nearly all authors agree to the need for isolating target areas or the entire liver to improve the 
procedure efficiency. This vascular isolation could be partial or complete.
Firstly, the implication of the complete vascular exclusion in the final efficacy of the procedure 
should be evaluated in order to determine its relevance. As previously reported, the complete liver 
vascularization of the pig can be occluded up to 20 min without neither hepatic injury nor systemic 
damage [52]. Considering this fact, Carreño et al. [50] described in pigs a surgical procedure to 
completely exclude liver vascularization ‘in vivo’ and perform hydrodynamic gene delivery, tar-
geting the entire organ. A complete midline laparotomy was carried out, exposing all the abdomi-
nal organs. The clamping sequence was as follows: first, the hepatic artery, then the portal vein 
and finally the infrahepatic vena cava, to interrupt hepatic inflow. The suprahepatic vena cava 
was clamped last, to secure total hepatic vascular exclusion. Depending on the flow sense of gene 
transfer, three different models were designed. In model 1 the portal vein was clamped, and only a 
longitudinal incision was made on the anterior surface of the cava vein to insert the perfusion can-
nula. In model 2, the process was the same as in model 1 but with the clamping of the vena cava and 
perfusion through the portal vein. In model 3 (Figure 4), the gene solution was injected simultane-
ously through suprahepatic IVC (Inferior Vena Cava) and the portal vein employing two catheters 
connected by a Y connector and a high-volume pump. After solution perfusion, the liver was kept 
under total vascular exclusion for no more than 5 min to allow gene penetration into the cell nuclei.
In all three models, when suprahepatic IVC was occluded and liver vasculature was com-
pletely excluded, the systemic pressure decreased rapidly. However, 1 min after revascular-
ization this parameter was entirely normalized and animals recovered in few hours. Due to 
the invasiveness of the surgical procedure that included a laparotomy, same authors designed 
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Figure 5. Single-lobe catheterization by balloon-catheter. Left panel is a schematic figure of catheter localization. Only 
the hepatic vein employed for gene transfer is occluded. Suprahepatic IVC, infrahepatic IVC and portal vein are not 
closed. Right panel shows two radiologic images of catheter position and iodinated contrast solution injection in single 
lobes defining the area affected by solution injected. The gene solution is injected through hepatic veins. The backflow 
is blocked by inflated balloon [54].
a technique for liver venous sealing mediated by image-guided catheterization [53]. Two 
strategies with different degrees of liver vasculature closure were proposed:
a. Inject the gene solution through a balloon catheter placed in a single lobe (Figure 5), and 
only target this part of the liver and
b. Place simultaneously three catheters with balloons within suprahepatic IVC, infrahepatic 
IVC and portal vein around the liver entry (Figure 6) in order to close its vasculature. The 
gene solution is injected through the catheter placed in suprahepatic IVC and the entire 
organ is targeted.
These three procedures, surgery and open and closed catheterization, proved to be safe. After 
gene transfer and animal awakening, their recovery was very fast and presented normal 
Figure 4. Schematic figure of liver simultaneous cava and porta perfusion with laparotomy surgery. Suprahepatic 
inferior vena cava and hepatic artery are ligated, and gene solution is transferred simultaneously by portal vein and 
infrahepatic inferior vena cava. Modified from [50].
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behavior few hours after the intervention. Furthermore, all of them mediated tissue expression 
of the protein encoded by the transferred gene. The rate of protein translation showed a direct 
relation with the degree of vasculature closure: surgery-mediated complete liver vasculature 
exclusion > catheterization-mediated venous vasculature closure > catheterization-mediated 
single lobe without organ vasculature closure.
Transferring the human alpha-1-antitrypsin, the single liver lobe strategy mediated 20,000 cop-
ies of protein per cell in the liver. Targeting the entire organ with the closure of suprahepatic 
IVC, infrahepatic IVC and portal vein mediated a higher translation rate up to 100,000 cop-
ies per cell. The complete exclusion of liver vasculature by occlusion IVC, portal vein and 
hepatic artery with surgical procedure increased this rate up to 400,000 copies per cell in 
the liver tissue. The highest rate of tissue translation achieved was only 10-fold lower than 
the one obtained with the successful gold standard procedure performed in the mouse. This 
suggests that the hydrodynamic procedure of liver gene therapy with vascular exclusion 
mediated by radiological and surgical strategies mediated efficient delivery with efficacious 
translation protein.
Once proved the efficiency of these procedures in pig and the confirmation of their safety for 
gene transfer ‘in vivo,’ the following step of translational process consisted of demonstrating 
the efficacy in human liver tissue.
Figure 6. Whole liver catheterization by balloon-catheters. Upper panel is a schematic figure of catheters localization. 
Infrahepatic IVC and portal vein are closed at liver access by inflated balloon-catheters. Lower left panel shows a 
radiologic image of supra and infrahepatic IVC catheters position. Lower mid panel shows an inflated balloon-catheter 
placed at portal vein blocking its exit. Lower right panel shows the iodinated contrast solution injection in the entire 
liver. The gene solution is injected through suprahepatic inferior vena cava [54].
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In this sense, human liver segments proceeding from surgical resection in patients with cancer 
were injected with different genes to evaluate the potential transferability of this technique. 
Given their precedence, the vasculature of these human liver segments is entirely excluded 
so they are watertight and hence, pressurized. The gene is retrogradely transfected through 
a catheter placed in a hepatic vein (Figure 7) and the segment remains watertight for 5 min.
The first studies of gene transfer with human liver segments [56] used the eGFP tracer gene in 
order to easily determine its expression efficacy, and it was demonstrated that the gene could be 
efficiently delivered and the protein was produced within the liver tissue as observed by fluores-
cence microscopy. After confirming the feasibility of the technique in this type of tissue, genes 
with clinical interest were employed to define the translational potential to clinical real settings.
Sendra Gisbert et al. [55] transferred a plasmid bearing the human interleukin-10 gene (IL10). 
Interleukin-10 is an immunomodulatory protein with pleotropic effects with potential inter-
est for the treatment of inflammatory diseases or for inducing tolerance in organ transplan-
tation. The rate of tissue protein translation achieved was around 1000 copies per cell, this 
meaning the potential therapeutic production of protein (IC50 of IL10 for TNFa = 124 pg) if 
compared with other results of the same group.
Our group also transferred in similar human liver segments a plasmid with the same human 
alpha-1-antitrypsin employed in mice and pigs but modified. In order to permit differing 
endogenous and exogenous genes and proteins, a sequence of nucleotides encoding the flag 
peptide was added. Preliminary experiments demonstrate that the procedure is efficient and 
the use of a human gene in human tissue favors the production of protein. First, results 
prove a rate of tissue protein translation of 104–105 copies of hAAT-flag protein per cell, this 
accounting for up to 22% of all the hAAT proteins present in the liver tissue in 1 week.
The efficacy of gene transfer can be measured by different techniques and authors have studied 
many variables to present their results and evaluate how efficient a procedure is. This requires 
the use of a more detailed analysis that allows to identify the effectiveness of each of the stages 
of the process of delivery of the gene, its decoding of protein and its subsequent location.
Figure 7. Catheterization of human liver segment. Left panel shows a schematic figure of a human liver segment with a 
catheter placed in a hepatic vein. Right panel is a radiographic image of a human liver segment injected with iodinated 
contrast solution through hepatic vein. Modified from [55].
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The molecular quantitative evaluation of decoding is demanding for a correct interpretation 
of the process. Quantitative determination of the molecular process provides real data of 
delivery, transcription and translation indexes. It would be important that researches achieved 
an agreement in data quantitation and expression to be able to objectively compare results and 
define the better conditions for gene transfer. The units should be expressed in molecular units 
(as number of copies or moles) or other units of mass. It is also very important that the data are 
referred to a common circumstance, such as a standard or ‘normalized cell.’ The normalized 
cell is defined as ‘typical mammalian hepatocyte with defined content of total DNA’ (genome 
weight of each specific animal, for instance, human: 6.6 pg), RNA (20 pg) and protein (500 pg).
This strategy offers an objective analysis that permits expressing the data as the copy number 
of each molecular specie, considering the standard content of DNA, RNA and protein in a 
normalized cell. This offers a more comprehensive interpretation of the entire process and 
permits comparing the results among different works and research groups.
To sum up, the hydrodynamic procedure is an efficient strategy for gene delivery demonstrated 
by the levels of tissue protein that is observed. The more the vasculature is occluded, the better 
is the final protein expression. The surgical procedure permits, excluding liver, entire vascula-
ture and mediates the higher expression rate. However, non-invasive image-guided catheter-
ization permits good levels of protein production without the need of a laparotomy incision.
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